tirzepatide for fibromyalgia as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis COULD “SKINNY SHOTS” CURE FIBROMYALGIA?

The SELECT trial established semaglutide as the first obesity drug to demonstrate cardiovascular risk reduction in a dedicated outcomes trial

Clinical Evidence Current clinical evidence for both peptides remains notably limited in comparison to the extensive body of preclinical data

While blood pressure reduction contributes, other mechanisms are also involved

The combination of exercise-induced heart rate elevation plus stimulant effects may feel uncomfortable and potentially stress the cardiovascular system unnecessarily

The peptide molecules are clustering at a submicroscopic level, reducing potency without any visible change